Kymera Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

kymeratx.com

Founded Year

2017

Stage

IPO | IPO

Total Raised

$197M

Date of IPO

8/21/2020

Market Cap

1.75B

Stock Price

33.77

About Kymera Therapeutics

Kymera Therapeutics (NASDAQ: KYMR) is a biotechnology company that develops an approach to treating previously untreatable diseases. Kymera aims to accelerate drug discovery with an ability to target and degrade proteins and advance treatment options for patients.

Kymera Therapeutics Headquarters Location

300 Technology Square 2nd Floor

Cambridge, Massachusetts, 02139,

United States

857-285-5314

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Kymera Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Kymera Therapeutics in 1 CB Insights research brief, most recently on Mar 16, 2020.

Expert Collections containing Kymera Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kymera Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Kymera Therapeutics Patents

Kymera Therapeutics has filed 12 patents.

The 3 most popular patent topics include:

  • Proteins
  • Transcription factors
  • Cell biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/21/2018

6/14/2022

Proteins, Transcription factors, Cell biology, G protein coupled receptors, Rare diseases

Grant

Application Date

9/21/2018

Grant Date

6/14/2022

Title

Related Topics

Proteins, Transcription factors, Cell biology, G protein coupled receptors, Rare diseases

Status

Grant

Latest Kymera Therapeutics News

The economy is in a downturn, and top biotech VCs are favoring startups that can bring in revenue over companies chasing cool id...

Aug 12, 2022

Redeem now Biotech investors are prioritizing revenue-making startups during the market downturn. In the past, VCs were willing to take a chance on companies that had unproven concepts. Now they're turning to biotechs that are selling services to other companies to bring in revenue. Biotech investors are adjusting their priorities during a long market downturn , prioritizing startups with a quicker path to generating revenue. The growing interest in near-term revenue contrasts with the classic biotech startup that burns through hundreds of millions of dollars over several years to try to produce a single approved drug. Several venture capitalists told Insider that biotechs that are making money — or that are close to that point — are more recession-proof. That's a major shift from the bull market of a year ago, when biotechs with unproven technology could fetch high valuations. Investors bought into the notion that if these companies' technology worked, they could produce more drugs at a lower cost. Some of these companies, like Sana Biotechnology and Lyell Immunopharma , raised hundreds of millions and went public in 2021 before their therapies had started initial human testing. But the market downturn — the SPDR S&P Biotech ETF, a leading biotech index, is down 25% over the past year — has investors shifting away from cool science projects and toward businesses grounded in actual products and revenue. "The pendulum is swinging," Chris Garabedian, a venture-portfolio manager at Perceptive Advisors, told Insider in July. VCs look for early startups with multiple paths to success Chris Garabedian worked at biotech companies for decades before investing in them. Perceptive Advisors One example of a startup that's attractive to VCs like Garabedian right now is A-Alpha Bio , a Seattle company selling its machine-learning technology to other drugmakers. Its technology runs millions of tests to see how an experimental drug interacts with a range of proteins, which can uncover whether it might work, as well as any toxicities. The startup, spun out of the University of Washington, is already generating revenue, though the company declined to disclose an exact figure. It has partnered with other biotechs, including Kymera Therapeutics and Twist Bioscience. A-Alpha is "not reliant on the old, binary nature of a drug-development program," Garabedian said last month, referring to the long and expensive process of bringing an experimental drug through clinical studies. "We're investing more in companies that can generate revenue and that can do partnerships. A-Alpha hits that perfectly." Surf Bio is another startup pitching a quicker path to cash, said Garabedian, who recently invested in the firm. The California startup raised a $16 million seed round this April to advance its technology designed to improve the performance of existing drugs. While it's working on its own project, a fast-acting insulin, it's also looking to sell its technology to other drug companies, Garabedian said. Rod Wong, a managing partner at RTW Investments, told Insider in July that with the downturn, he now goes into an investment with the "conservative assumption" that RTW might be the primary capital provider for some time. That assumption guides some of the firm's investments, he said, adding that it's easier to back companies that already have a drug on the commercial market. Revenue from those sales can lessen capital needs. "It makes it easier to underwrite or invest in those companies," Wong said at the time. "We are finding probably a bit more opportunity in those kinds of companies than we did before." Jeff Huber, cofounder and general partner of Triatomic Capital Triatomic Capital Jeff Huber, a cofounder and general partner of Triatomic Capital, told Insider last month that he looks for multiple paths to success in each investment. His firm led a $40 million Series A round in July for Manifold Bio , a Boston startup developing a barcoding platform to improve animal drug research. Huber said the company is developing its own drugs but has also seen "strong interest" from other drugmakers wanting to use its technology. "Even if their therapeutic pipeline didn't pan out, there's still a good and strong platform business providing that as a service to other biopharma companies," he told Insider. Deborah Palestrant, a partner at 5AM Ventures, also said in July that investment dollars had shifted toward more surefire companies that can hit milestones over the next few years that would move the company forward. Investors today, she said, aren't as prone to saying: "Hey, this is a cool idea. I'm just going to give it some money and let it go." Sign up for notifications from Insider! Stay up to date with what you want to know. Subscribe to push notifications

Kymera Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kymera Therapeutics Rank

  • When was Kymera Therapeutics founded?

    Kymera Therapeutics was founded in 2017.

  • Where is Kymera Therapeutics's headquarters?

    Kymera Therapeutics's headquarters is located at 300 Technology Square, Cambridge.

  • What is Kymera Therapeutics's latest funding round?

    Kymera Therapeutics's latest funding round is IPO.

  • How much did Kymera Therapeutics raise?

    Kymera Therapeutics raised a total of $197M.

  • Who are the investors of Kymera Therapeutics?

    Investors of Kymera Therapeutics include Janus Henderson Investors, BlackRock, Bain Capital, Leukemia & Lymphoma Society, BVF Partners and 16 more.

  • Who are Kymera Therapeutics's competitors?

    Competitors of Kymera Therapeutics include Pin Therapeutics and 1 more.

You May Also Like

Amphista Therapeutics Logo
Amphista Therapeutics

Amphista Therapeutics is a biopharmaceutical company that creates cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease-causing proteins.

P
Pin Therapeutics

Pin Therapeutics is a pharmaceutical company that creates therapeutic products based on chemical biology-driven protein degradation, including PROTAC technology. The company aims to develop PROTAC compounds for oncology, neurodegenerative diseases, and cardiovascular indications based on disease-agnostic approaches.

F
FIMECS

FIMECS is a drug discovery biotech firm focused on developing protein degradation therapeutics for cancers and other difficult-to-treat diseases.

Arvinas Logo
Arvinas

Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation approaches into drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients.

Nurix Therapeutics Logo
Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. The drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

C4 Therapeutics Logo
C4 Therapeutics

C4 Therapeutics (NASDAQ: CCCC) advances a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.